Details for Patent: 10,406,143

Which drugs does patent 10,406,143 protect, and when does it expire?

Patent 10,406,143 protects GALAFOLD and is included in one NDA.

This patent has forty-one patent family members in seventeen countries.

Summary for Patent: 10,406,143

Title:	Methods for treatment of fabry disease
Abstract:	Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
Inventor(s):	Lockhart; David J. (Emerald Hills, CA), Castelli; Jeff (New Hope, PA)
Assignee:	Amicus Therapeutics, Inc. (Cranbury, NJ)
Application Number:	15/974,222
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,406,143
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,406,143

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes						THE TREATMENT OF FABRY PATIENTS

International Family Members for US Patent 10,406,143

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2787345		300843	Netherlands
European Patent Office	2787345		PA2016033	Lithuania
European Patent Office	2787345		122016000090	Germany
European Patent Office	2787345		CA 2016 00055	Denmark
European Patent Office	2787345		93312	Luxembourg